Close Menu

NEW YORK (GenomeWeb News) – Proteome Sciences said today that it will collaborate with CHDI Foundation on research into protein biomarkers for Huntington's disease.

Under the collaboration, the London-based company will use its Tandem Mass Tag reagents to develop mass spectrometry-based high density protein expression maps in cell lines carrying different levels of the CAG-repeat genetic alteration linked to Huntington's.

The work will be done at Proteome Sciences' ISO 9001:2008 certified facility in Frankfurt. Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.